Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

Next Previous
X
Search
Trial Profile

A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD-8186 (Primary) ; Docetaxel (Primary)
  • Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 26 Sep 2023 Planned End Date changed from 27 Mar 2024 to 22 Sep 2024.
    • 29 Mar 2023 Planned End Date changed from 1 Apr 2023 to 27 Mar 2024.
    • 02 Apr 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top